TI
AVDL

Trexquant Investment’s Avadel Pharmaceuticals AVDL Stock Holding History

Trexquant Investment’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-410,500
Closed -$6.27M – 1577
2025
Q3 		$6.27M Sell
410,500
-72,900
-15% -$949K 0.06% 454
2025
Q2 		$4.28M Buy
483,400
+354,221
+274% +$3.11M 0.05% 594
2025
Q1 		$1.01M Buy
+129,179
New +$1.08M 0.01% 1088
2024
Q4 		– Sell
-44,811
Closed -$588K – 1544
2024
Q3 		$588K Buy
+44,811
New +$683K 0.01% 1213
2023
Q2 		– Sell
-42,435
Closed -$389K – 1426
2023
Q1 		$389K Buy
+42,435
New +$349K 0.01% 1094
2022
Q1 		– Sell
-23,500
Closed -$190K – 1344
2021
Q4 		$190K Buy
+23,500
New +$215K 0.01% 1161
2018
Q3 		– Sell
-10,839
Closed -$66K – 942
2018
Q2 		$66K Sell
10,839
-34,567
-76% -$242K ﹤0.01% 852
2018
Q1 		$331K Buy
45,406
+31,030
+216% +$273K 0.02% 781
2017
Q4 		$118K Sell
14,376
-21,842
-60% -$205K 0.01% 997
2017
Q3 		$380K Buy
36,218
+5,718
+19% +$54.6K 0.1% 375
2017
Q2 		$336K Buy
30,500
+7,169
+31% +$72K 0.09% 405
2017
Q1 		$226K Buy
23,331
+11,031
+90% +$110K 0.03% 905
2016
Q4 		$128K Buy
+12,300
New +$135K 0.02% 890
2016
Q2 		– Sell
-105,369
Closed -$1.16M – 865
2016
Q1 		$1.16M Buy
+105,369
New +$1.05M 0.14% 245
2015
Q4 		– Sell
-60,100
Closed -$980K – 1001
2015
Q3 		$980K Buy
60,100
+44,430
+284% +$979K 0.08% 423
2015
Q2 		$332K Sell
15,670
-36,630
-70% -$657K 0.04% 778
2015
Q1 		$940K Buy
52,300
+32,100
+159% +$503K 0.1% 395
2014
Q4 		$346K Buy
+20,200
New +$288K 0.06% 622

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trexquant Investment's AVDL Position: Q4 2025 in Review

Trexquant Investment sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 410,500 shares — an estimated $6.27M sold.

Trexquant Investment first reported a position in AVDL in Q4 2014 and held it in 18 quarters. The position peaked at $6.27M in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Trexquant Investment reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Trexquant Investment sold 410,500 Avadel Pharmaceuticals shares in Q4 2025, an estimated $6.27M.
  • Trexquant Investment first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 18 quarters.
  • Trexquant Investment's Avadel Pharmaceuticals position peaked at $6.27M in Q3 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Trexquant Investment's 13F filing for Q4 2025, filed 17 Feb 2026.